Substituted N-aryl-6-pyrimidinones: A new class of potent, selective, and orally active p38 MAP kinase inhibitors.
Devadas, B., Selness, S.R., Xing, L., Madsen, H.M., Marrufo, L.D., Shieh, H., Messing, D.M., Yang, J.Z., Morgan, H.M., Anderson, G.D., Webb, E.G., Zhang, J., Devraj, R.V., Monahan, J.B.(2011) Bioorg.Med.Chem.Lett. 21: 3856-3860
- PubMed: 21620699 
- DOI: 10.1016/j.bmcl.2011.05.006
- PubMed Abstract: 
A novel series of highly potent and selective p38 MAP kinase inhibitors was developed originating from a substituted N-aryl-6-pyrimidinone scaffold. SAR studies coupled with in vivo evaluations in rat arthritis model culminated in the identification ...